2. Seol H, Lee HJ, Choi Y et al. Intratumoral heterogeneity of HER2 geneamplification in breast cancer: its clinicopathological significance. Mod Pathol 2012; 25:938-948. 3. Shafi H, Astvatsaturyan K, Chung F et al. Clinicopathological significance of...
[11]Kurozumi S,et al.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.Breast Cancer Res Treat 2016;158:99–111. [12]Parker JS,et al.Supervised Risk Predictor ...
[26]Dzimitrowicz H,et al.T-DM1 activity in metastatic human epidermal growth factor receptor 2–positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab.J Clin Oncol 2016;34:3511–7. [27]Vici P,Pizzuti L,et al.A retrospective multicentric observational study of trastuz...
[11]Kurozumi S,et al.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.Breast Cancer Res Treat 2016;158:99–111. [12]Parker JS,et al.Supervised Risk Predictor of Breast Cancer Based on Intrins...
13. Miglietta F, Griguolo G, Bottosso M, et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer. 2022 May 20;8(1):66. 14. 刘月平, 薛卫成, 杨文涛, 等. 乳腺癌HER2低表达病理检测进展及挑战 [J] . 中华病理...
[1] HER2-low breast cancer, Molecular characteristics andprognosis,Cancers, 2021;13:2824 [2] Prevalence of HER2 low in breast cancer subtypes using the VENANA anti-HER2/neu (4B5) assay [J]. J Clin Oncol, 2021, 39 (15_Suppl): 1021. [3] Antitumor activity and safetyof trastuzumab der...
[5]Yoon KH, Park Y, Kang E, et al. Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer[J]. Cancer Res Treat, 2021 [Ahead of print]. [6]Chen T, Zhang N, Moran MS, et al. Borderline ER-positive primary breast cancer gains no signific...
[12]Kim, Min Chong et al. “Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer.” Journal of breast cancer vol. 25,4 (2022): 318-326. doi:10.4048/jbc.2022.25.e31 [13]Trastuzumab Deruxtecan vs Treatmentof Physician's Choice in Patients With HER2-Low Unresectable ...
HER2/neu(also known as ErbB-2,ERBB2) is a member of theErbBprotein family, more commonly known as theepidermal growth factor receptor family. HER2/neu is notable for its role in the pathogenesis of breast cancer and as a target of treatment. It is a cell membrane surface-boundreceptor ty...
如图A所示,HER家族由四个成员组成:HER1,又称表皮生长因子受体(EGFR);HER2,由ERBB2(又称neu)基因编码;HER3;HER4。至少11种已知的肽类生长因子(配体)可以结合至HER1(表皮生长因子EGF,肝素结合EGF样生长因子HBEGF,β细胞素,转化生长因子TGFα,双向调节因子或双调蛋白,...